Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC)
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
At a glance
- Drugs INGN 225 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 May 2018 Status changed from active, no longer recruiting to recruiting.
- 29 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.